



Clinical trial results:

A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis (CF) Who Are Homozygous or Heterozygous for the F508del Mutation

Summary

EudraCT number	2018-000185-11
Trial protocol	SE DE GB CZ BE NL AT GR FR IT
Global end of trial date	09 January 2023

Results information

Result version number	v2 (current)
This version publication date	25 May 2024
First version publication date	23 July 2023
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	VX17-445-105
-----------------------	--------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03525574
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Vertex Pharmaceuticals Incorporated
Sponsor organisation address	50 Northern Avenue, Boston, Massachusetts, United States,
Public contact	Medical Monitor, Vertex Pharmaceuticals Incorporated, +1 617-341-6777, medicalinfo@vrtx.com
Scientific contact	Medical Monitor, Vertex Pharmaceuticals Incorporated, +1 617-341-6777, medicalinfo@vrtx.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-002324-PIP01-17
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	06 February 2023
Is this the analysis of the primary completion data?	Yes
Primary completion date	09 January 2023
Global end of trial reached?	Yes
Global end of trial date	09 January 2023
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the long-term safety and tolerability of VX-445 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who were homozygous or heterozygous for the F508del mutation.

Protection of trial subjects:

The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and the International Conference on Harmonization (ICH) Guideline for Good Clinical Practice (GCP).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	09 October 2018
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy, Safety
Long term follow-up duration	56 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 32
Country: Number of subjects enrolled	Sweden: 4
Country: Number of subjects enrolled	United Kingdom: 31
Country: Number of subjects enrolled	Austria: 13
Country: Number of subjects enrolled	Belgium: 32
Country: Number of subjects enrolled	Czechia: 6
Country: Number of subjects enrolled	France: 19
Country: Number of subjects enrolled	Germany: 17
Country: Number of subjects enrolled	Greece: 3
Country: Number of subjects enrolled	Italy: 21
Country: Number of subjects enrolled	United States: 280
Country: Number of subjects enrolled	Canada: 25
Country: Number of subjects enrolled	Australia: 24
Worldwide total number of subjects	507
EEA total number of subjects	147

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	145
Adults (18-64 years)	362
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Subjects from the parent studies VX17-445-102 (NCT03525444) and VX17-445-103 (NCT03525548) were enrolled in this study. A total of 507 subjects were enrolled in this study.

Period 1

Period 1 title	Treatment Period
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Treatment Period: ELX/TEZ/IVA
-----------	-------------------------------

Arm description:

Subjects received ELX 200 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hrs (q12h) in the treatment period for 192 weeks.

Arm type	Experimental
Investigational medicinal product name	IVA
Investigational medicinal product code	VX-770
Other name	ivacaftor
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received IVA once daily in the evening.

Investigational medicinal product name	ELX/TEZ/IVA
Investigational medicinal product code	VX-445/VX-661/VX-770
Other name	elexacaftor/tezacaftor/ivacaftor
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received VX-445/TEZ/IVA TC, once daily in the morning.

Number of subjects in period 1 ^[1]	Treatment Period: ELX/TEZ/IVA
Started	506
Completed	354
Not completed	152
Physician decision	6
Commercial Drug is Available for Subject	48
Death	1
Other	58
Adverse event	15

Other non-compliance	2
Lost to follow-up	4
Withdrawal of consent (not due to AE)	18

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: A total 507 subjects were enrolled from the parent studies. One subject is enrolled but did not dosed in the study. Therefore, data for 506 subjects are reported in the subject disposition and baseline sections.

Period 2

Period 2 title	Extension Period
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Extension Period: ELX/TEZ/IVA
------------------	-------------------------------

Arm description:

Subjects received ELX 200 mg qd/TEZ 100 mg qd /IVA 150 mg q12h in the extension period for 48 weeks.

Arm type	Experimental
Investigational medicinal product name	ELX/TEZ/IVA
Investigational medicinal product code	VX-445/VX-661/VX-770
Other name	elexacaftor/tezacaftor/ivacaftor
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received ELX/TEZ/IVA triple combination (TC), once daily in the morning.

Investigational medicinal product name	IVA
Investigational medicinal product code	VX-770
Other name	ivacaftor
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received IVA once daily in the evening.

Number of subjects in period 2^[2]	Extension Period: ELX/TEZ/IVA
Started	11
Completed	0
Not completed	11
Commercial Drug is Available for Subject	10
Other	1

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: A total of 507 subjects were enrolled in the parent studies on treatment period. However, only 11 subjects rolled over to extension period from treatment period of the study.

Baseline characteristics

Reporting groups

Reporting group title	Treatment Period: ELX/TEZ/IVA
-----------------------	-------------------------------

Reporting group description:

Subjects received ELX 200 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hrs (q12h) in the treatment period for 192 weeks.

Reporting group values	Treatment Period: ELX/TEZ/IVA	Total	
Number of subjects	506	506	
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	26.7 ± 10.7	-	
Gender categorical Units: Subjects			
Female	251	251	
Male	255	255	
Race Units: Subjects			
White	470	470	
Black or African American	4	4	
American Indian or Alaska Native	1	1	
Other	3	3	
Not collected per local regulations	25	25	
Multiple	3	3	
Ethnicity Units: Subjects			
Hispanic or Latino	21	21	
Not Hispanic or Latino	460	460	
Not collected per local regulations	25	25	

End points

End points reporting groups

Reporting group title	Treatment Period: ELX/TEZ/IVA
Reporting group description: Subjects received ELX 200 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hrs (q12h) in the treatment period for 192 weeks.	
Reporting group title	Extension Period: ELX/TEZ/IVA
Reporting group description: Subjects received ELX 200 mg qd/TEZ 100 mg qd /IVA 150 mg q12h in the extension period for 48 weeks.	
Subject analysis set title	OL-FAS 102/105
Subject analysis set type	Full analysis
Subject analysis set description: The OL Full Analysis Set (FAS) 102/105 included participants enrolled from parent study 102 who received at least 1 dose of study drug in this open label study.	
Subject analysis set title	OL-FAS 103/105
Subject analysis set type	Full analysis
Subject analysis set description: The OL-FAS 103/105 included participants enrolled from parent study 103 who received at least 1 dose of study drug in this open label study.	
Subject analysis set title	Cumulative Triple Combination (TC) Efficacy Set 102/105
Subject analysis set type	Full analysis
Subject analysis set description: Cumulative TC Efficacy Set 102/105 included all participants who were randomized to TC ELX/TEZ/IVA and received at least 1 dose of study drug during the parent study 102 and/or received at least 1 dose of study drug during this Open label study. Three participants from parent study 102 (not enrolled in this study) were included in this analysis set.	
Subject analysis set title	Cumulative TC Efficacy Set 103/105
Subject analysis set type	Full analysis
Subject analysis set description: Cumulative TC Efficacy Set 103/105 included all participants who were randomized to TC ELX/TEZ/IVA and received at least 1 dose of study drug during the parent study 103 and/or received at least 1 dose of study drug during this Open label study.	

Primary: Treatment Period: Safety and Tolerability as Assessed by Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

End point title	Treatment Period: Safety and Tolerability as Assessed by Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) ^[1]
End point description: The Open-Label Safety Set (OL-SS) included all subjects who had received at least 1 dose of study drug in the OL study.	
End point type	Primary
End point timeframe: From Day 1 up to Week 196	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistics were planned. No statistical comparisons were planned for the primary safety endpoint.

End point values	Treatment Period: ELX/TEZ/IVA			
Subject group type	Reporting group			
Number of subjects analysed	506			
Units: subjects				
Subjects With TEAEs	504			
Subjects With SAEs	175			

Statistical analyses

No statistical analyses for this end point

Primary: Extension Period: Safety and Tolerability as Assessed by Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

End point title	Extension Period: Safety and Tolerability as Assessed by Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) ^[2]
-----------------	---

End point description:

The Open-label Extension Period Safety Set (OL-EP-SS) include all subjects who have received at least 1 dose of study drug in the Extension Period of the OL study.

End point type	Primary
----------------	---------

End point timeframe:

From Day 1 up to Week 52

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistics were planned. No statistical comparisons were planned for the primary safety endpoint.

End point values	Extension Period: ELX/TEZ/IVA			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: subjects				
Subjects With TEAEs	7			
Subjects With SAEs	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Period: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 102/105 Efficacy Set

End point title	Treatment Period: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 102/105 Efficacy Set
-----------------	---

End point description:

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. This

analysis set included study 102 parent study subjects who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA. Baseline was defined as the parent study baseline. Here "n" signifies subjects who were evaluable for the specified category. The Open label Full Analysis Set (OL FAS) is defined as all enrolled subjects who have received at least 1 dose of study drug in the open label study.

End point type	Secondary
End point timeframe:	
From Baseline at 192 Week	

End point values	Treatment Period: ELX/TEZ/IVA			
Subject group type	Reporting group			
Number of subjects analysed	269			
Units: percentage points				
least squares mean (standard error)				
Placebo-ELX/TEZ/IVA (n=136)	15.3 (± 0.8)			
ELX/TEZ/IVA-ELX/TEZ/IVA (n=133)	13.8 (± 0.8)			

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Period: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 103/105 Efficacy Set

End point title	Treatment Period: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 103/105 Efficacy Set
-----------------	---

End point description:

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. This analysis set included study 103 parent study subjects who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA. Baseline was defined as the parent study baseline. Here "n" signifies subjects who were evaluable for the specified category. OL-FAS.

End point type	Secondary
End point timeframe:	
From Baseline at 192 Week	

End point values	Treatment Period: ELX/TEZ/IVA			
Subject group type	Reporting group			
Number of subjects analysed	68			
Units: percentage points				
least squares mean (standard error)				
TEZ/IVA-ELX/TEZ/IVA (n=32)	10.9 (± 1.3)			
ELX/TEZ/IVA-ELX/TEZ/IVA (n=36)	10.7 (± 1.3)			

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Period: Absolute Change in Sweat Chloride (SwCl) for 102/105 Efficacy Set

End point title	Treatment Period: Absolute Change in Sweat Chloride (SwCl) for 102/105 Efficacy Set
-----------------	---

End point description:

Sweat samples were collected using an approved collection device. This analysis set included study 102 parent study subjects who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA. Baseline was defined as the parent study baseline. Here "n" signifies subjects who were evaluable for the specified category. OL-FAS.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline at 192 Week

End point values	Treatment Period: ELX/TEZ/IVA			
Subject group type	Reporting group			
Number of subjects analysed	261			
Units: millimole per liter (mmol/L)				
least squares mean (standard error)				
Placebo-ELX/TEZ/IVA (n=133)	-47.0 (± 1.6)			
ELX/TEZ/IVA-ELX/TEZ/IVA (n=128)	-45.3 (± 1.6)			

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Period: Absolute Change in Sweat Chloride (SwCl) for 103/105 Efficacy Set

End point title	Treatment Period: Absolute Change in Sweat Chloride (SwCl) for 103/105 Efficacy Set
-----------------	---

End point description:

Sweat samples were collected using an approved collection device. This analysis set included study 103 parent study subjects who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA. Baseline was defined as the parent study baseline. Here "n" signifies subjects who were evaluable for the specified category. OL-FAS.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline at 192 Week

End point values	Treatment Period: ELX/TEZ/IVA			
Subject group type	Reporting group			
Number of subjects analysed	69			
Units: mmol/L				
least squares mean (standard error)				
TEZ/IVA-ELX/TEZ/IVA (n=31)	-48.2 (± 3.8)			
ELX/TEZ/IVA-ELX/TEZ/IVA (n=38)	-48.2 (± 3.5)			

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Period: Number of Pulmonary Exacerbations (PEx) for 103/105 Efficacy Set

End point title	Treatment Period: Number of Pulmonary Exacerbations (PEx) for 103/105 Efficacy Set
-----------------	--

End point description:

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Cumulative TC Efficacy Set is defined all subjects who were randomized to ELX/TEZ/IVA and received at least 1 dose of study drug during the parent study and/or received at least 1 dose of study drug during the Open label study. Baseline was defined as the parent study baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline at 192 Week

End point values	Cumulative TC Efficacy Set 103/105			
Subject group type	Subject analysis set			
Number of subjects analysed	107			
Units: PEx events				
number (not applicable)	43			

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Period: Number of Pulmonary Exacerbations (PEx) for 102/105 Efficacy Set

End point title	Treatment Period: Number of Pulmonary Exacerbations (PEx)
-----------------	---

End point description:

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Cumulative TC Efficacy Set is defined all subjects who were randomized to ELX/TEZ/IVA and received at least 1 dose of study drug during the parent study and/or received at least 1 dose of study drug during the Open label study. Baseline was defined as the parent study baseline.

End point type

Secondary

End point timeframe:

From Baseline at 192 Week

End point values	Cumulative Triple Combination (TC) Efficacy Set 102/105			
Subject group type	Subject analysis set			
Number of subjects analysed	403			
Units: PEx events				
number (not applicable)	174			

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Period: Time to First PEx for 102/105 Efficacy Set

End point title

Treatment Period: Time to First PEx for 102/105 Efficacy Set

End point description:

Time-to-first pulmonary exacerbation was analyzed using Kaplan-Meier estimates and expressed in terms of event-free probability. PEx was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Cumulative TC Efficacy Set is defined all subjects who were randomized to ELX/TEZ/IVA and received at least 1 dose of study drug during the parent study and/or received at least 1 dose of study drug during the Open label study. Baseline was defined as the parent study baseline. Here, 99999 indicates "Not Applicable" as median and 95% confidence interval could not be estimated because less than 50% of subjects had events.

End point type

Secondary

End point timeframe:

From Baseline at Week 192

End point values	Cumulative Triple Combination (TC) Efficacy Set 102/105			
Subject group type	Subject analysis set			
Number of subjects analysed	403			
Units: days				
median (confidence interval 95%)	99999 (99999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Period: Absolute Change in Body Mass Index (BMI) for 102/105 Efficacy Set

End point title	Treatment Period: Absolute Change in Body Mass Index (BMI) for 102/105 Efficacy Set
-----------------	---

End point description:

BMI was defined as weight in kilogram (kg) divided by height in square meter (m²). This analysis set included study 102 parent study subjects who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA. Baseline was defined as the parent study baseline. Here "n" signifies subjects who were evaluable for the specified category. OL-FAS.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline at Week 192

End point values	Treatment Period: ELX/TEZ/IVA			
Subject group type	Reporting group			
Number of subjects analysed	283			
Units: kilogram per meter square (kg/m ²)				
least squares mean (standard error)				
Placebo-ELX/TEZ/IVA (n=144)	1.81 (± 0.16)			
ELX/TEZ/IVA-ELX/TEZ/IVA (n=139)	1.74 (± 0.16)			

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Period: Time to First PEx for 103/105 Efficacy Set

End point title	Treatment Period: Time to First PEx for 103/105 Efficacy Set
-----------------	--

End point description:

Time-to-first pulmonary exacerbation was analyzed using Kaplan-Meier estimates and expressed in terms of event-free probability. PEx was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Cumulative TC Efficacy Set is defined all subjects who were randomized to ELX/TEZ/IVA and received at least 1 dose of study drug during the parent study and/or received at least 1 dose of study drug during the Open label study. Baseline was defined as the parent study baseline. Here, 99999 indicates "Not Applicable" as median and 95% confidence interval could not be estimated because less than 50% of subjects had events.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline at Week 192

End point values	Cumulative TC Efficacy Set 103/105			
Subject group type	Subject analysis set			
Number of subjects analysed	107			
Units: days				
median (confidence interval 95%)	99999 (99999 to 99999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Period: Absolute Change in Body Mass Index (BMI) for 103/105 Efficacy Set

End point title	Treatment Period: Absolute Change in Body Mass Index (BMI) for 103/105 Efficacy Set
-----------------	---

End point description:

BMI was defined as weight in kilogram (kg) divided by height in square meter (m²). This analysis set included study 103 parent study subjects who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA. Baseline was defined as the parent study baseline. Here "n" signifies subjects who were evaluable for the specified category. OL-FAS.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline at Week 192

End point values	Treatment Period: ELX/TEZ/IVA			
Subject group type	Reporting group			
Number of subjects analysed	74			
Units: kg/m ²				
least squares mean (standard error)				
TEZ/IVA-ELX/TEZ/IVA (n=32)	1.72 (± 0.24)			
ELX/TEZ/IVA-ELX/TEZ/IVA (n=42)	1.85 (± 0.22)			

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Period: Absolute Change in BMI Z-score for 102/105 Efficacy

Set

End point title	Treatment Period: Absolute Change in BMI Z-score for 102/105 Efficacy Set
-----------------	---

End point description:

BMI was defined as weight in kg divided by height in m². Z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher BMI. This analysis set included study 102 parent study subjects who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA. Baseline was defined as the parent study baseline. Here "n" signifies subjects who were evaluable for the specified category. OL-FAS.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline at Week 192

End point values	Treatment Period: ELX/TEZ/IVA			
Subject group type	Reporting group			
Number of subjects analysed	57			
Units: z-score				
least squares mean (standard error)				
Placebo-ELX/TEZ/IVA (n=34)	0.24 (± 0.09)			
ELX/TEZ/IVA-ELX/TEZ/IVA (n=23)	0.18 (± 0.09)			

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Period: Absolute Change in BMI Z-score for 103/105 Efficacy Set

End point title	Treatment Period: Absolute Change in BMI Z-score for 103/105 Efficacy Set
-----------------	---

End point description:

BMI was defined as weight in kg divided by height in m². Z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher BMI. This analysis set included study 103 parent study subjects who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA. Baseline was defined as the parent study baseline. Here "n" signifies subjects who were evaluable for the specified category. OL-FAS.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline at Week 192

End point values	Treatment Period: ELX/TEZ/IVA			
Subject group type	Reporting group			
Number of subjects analysed	15			
Units: z-score				
least squares mean (standard error)				
TEZ/IVA-ELX/TEZ/IVA (n=8)	0.36 (± 0.14)			
ELX/TEZ/IVA-ELX/TEZ/IVA(n=7)	0.24 (± 0.15)			

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Period: Absolute Change in Body Weight for 102/105 Efficacy Set

End point title	Treatment Period: Absolute Change in Body Weight for 102/105 Efficacy Set
-----------------	---

End point description:

This analysis set included study 102 parent study subjects who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA. Baseline was defined as the parent study baseline. Here "n" signifies subjects who were evaluable for the specified category. OL-FAS.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline at Week 192

End point values	Treatment Period: ELX/TEZ/IVA			
Subject group type	Reporting group			
Number of subjects analysed	283			
Units: kg				
least squares mean (standard error)				
Placebo-ELX/TEZ/IVA (n=144)	6.6 (± 0.5)			
ELX/TEZ/IVA-ELX/TEZ/IVA (n=139)	6.0 (± 0.5)			

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Period: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 102/105 Efficacy Set

End point title	Treatment Period: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 102/105 Efficacy Set
-----------------	--

End point description:

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for

participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. This analysis set included study 102 parent study subjects who received Placebo- ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA. Baseline was defined as the parent study baseline. Here "n" signifies subjects who were evaluable for the specified category. OL-FAS.

End point type	Secondary
End point timeframe:	
From Baseline at Week 192	

End point values	Treatment Period: ELX/TEZ/IVA			
Subject group type	Reporting group			
Number of subjects analysed	295			
Units: units on a scale				
least squares mean (standard error)				
Placebo-ELX/TEZ/IVA (n=148)	15.3 (± 1.5)			
ELX/TEZ/IVA-ELX/TEZ/IVA (n=147)	18.3 (± 1.5)			

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Period: Absolute Change in Body Weight for 103/105 Efficacy Set

End point title	Treatment Period: Absolute Change in Body Weight for 103/105 Efficacy Set
End point description:	
This analysis set included study 103 parent study subjects who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA. Baseline was defined as the parent study baseline. Here "n" signifies subjects who were evaluable for the specified category. OL-FAS.	
End point type	Secondary
End point timeframe:	
From Baseline at Week 192	

End point values	Treatment Period: ELX/TEZ/IVA			
Subject group type	Reporting group			
Number of subjects analysed	74			
Units: kg				
least squares mean (standard error)				
TEZ/IVA-ELX/TEZ/IVA (n=32)	6.1 (± 0.8)			
ELX/TEZ/IVA-ELX/TEZ/IVA (n=42)	6.3 (± 0.7)			

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Period: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 103/105 Efficacy Set

End point title	Treatment Period: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 103/105 Efficacy Set
-----------------	--

End point description:

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. This analysis set included study 103 parent study subjects who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA. Baseline was defined as the parent study baseline. Here "n" signifies subjects who were evaluable for the specified category. OL-FAS.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline at Week 192

End point values	Treatment Period: ELX/TEZ/IVA			
Subject group type	Reporting group			
Number of subjects analysed	75			
Units: units on a scale				
least squares mean (standard error)				
TEZ/IVA-ELX/TEZ/IVA (n=33)	14.8 (± 2.6)			
ELX/TEZ/IVA-ELX/TEZ/IVA (n=42)	17.6 (± 2.4)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events (AE) are reported separately for both Periods. Treatment period covers 1st dose till 196 weeks in treatment period; extension period covers 1st dose in extension period till safety follow-up or end of study, whichever occurs first.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	25.1

Reporting groups

Reporting group title	Extension Period: ELX/TEZ/IVA
-----------------------	-------------------------------

Reporting group description:

Subjects received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the extension period for 48 weeks.

Reporting group title	Treatment Period: ELX/TEZ/IVA
-----------------------	-------------------------------

Reporting group description:

Subjects received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 192 weeks.

Serious adverse events	Extension Period: ELX/TEZ/IVA	Treatment Period: ELX/TEZ/IVA	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 11 (0.00%)	175 / 506 (34.58%)	
number of deaths (all causes)	0	1	
number of deaths resulting from adverse events		0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma of colon			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Philadelphia positive acute lymphocytic leukaemia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Uterine leiomyoma			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive urgency			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 11 (0.00%)	2 / 506 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug withdrawal syndrome			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fatigue			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Physical deconditioning			

subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Breast mass			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Testicular torsion			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sputum increased			
subjects affected / exposed	0 / 11 (0.00%)	2 / 506 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory distress			

subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Productive cough			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonitis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung infiltration			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rales			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory failure			
subjects affected / exposed	0 / 11 (0.00%)	2 / 506 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoptysis			

subjects affected / exposed	0 / 11 (0.00%)	11 / 506 (2.17%)	
occurrences causally related to treatment / all	0 / 0	2 / 19	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemothorax			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Suicide attempt			
subjects affected / exposed	0 / 11 (0.00%)	2 / 506 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol withdrawal syndrome			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anger			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anorexia nervosa			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anxiety			
subjects affected / exposed	0 / 11 (0.00%)	2 / 506 (0.40%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bipolar disorder			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			

subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Major depression			
subjects affected / exposed	0 / 11 (0.00%)	3 / 506 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental disorder			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric decompensation			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychotic disorder			
subjects affected / exposed	0 / 11 (0.00%)	2 / 506 (0.40%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
SARS-CoV-2 test positive			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary function test decreased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza A virus test positive			
subjects affected / exposed	0 / 11 (0.00%)	2 / 506 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Human rhinovirus test positive			

subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alanine aminotransferase increased			
subjects affected / exposed	0 / 11 (0.00%)	5 / 506 (0.99%)	
occurrences causally related to treatment / all	0 / 0	4 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 11 (0.00%)	5 / 506 (0.99%)	
occurrences causally related to treatment / all	0 / 0	4 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial test positive			
subjects affected / exposed	0 / 11 (0.00%)	2 / 506 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood bilirubin increased			
subjects affected / exposed	0 / 11 (0.00%)	2 / 506 (0.40%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterovirus test positive			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gamma-glutamyltransferase increased			

subjects affected / exposed	0 / 11 (0.00%)	2 / 506 (0.40%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Craniocerebral injury			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural pneumothorax			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fracture of penis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb injury			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar vertebral fracture			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax traumatic			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol poisoning			

subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary contusion			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radius fracture			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib fracture			
subjects affected / exposed	0 / 11 (0.00%)	2 / 506 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scapula fracture			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin injury			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia fracture			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			

subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Traumatic haemothorax			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular access site pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound dehiscence			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Cystic fibrosis lung			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute left ventricular failure			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myocardial infarction			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Pericarditis constrictive			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postural orthostatic tachycardia syndrome			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial effusion			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Cerebral infarction			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic encephalopathy			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Miller Fisher syndrome			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebellar infarction			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Optic neuritis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autonomic nervous system imbalance			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Leukocytosis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Visual impairment			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Duodenitis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	0 / 11 (0.00%)	4 / 506 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal adhesions			

subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal hernia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			
subjects affected / exposed	0 / 11 (0.00%)	2 / 506 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	0 / 11 (0.00%)	3 / 506 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cyclic vomiting syndrome			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Distal intestinal obstruction syndrome			
subjects affected / exposed	0 / 11 (0.00%)	9 / 506 (1.78%)	
occurrences causally related to treatment / all	0 / 0	2 / 25	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric fistula			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			

subjects affected / exposed	0 / 11 (0.00%)	2 / 506 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	0 / 11 (0.00%)	5 / 506 (0.99%)	
occurrences causally related to treatment / all	0 / 0	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngo-oesophageal diverticulum			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	0 / 11 (0.00%)	6 / 506 (1.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal perforation			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric haemorrhage			

subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	0 / 11 (0.00%)	3 / 506 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertransaminaemia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis chronic			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Calculus urinary			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Acute kidney injury			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal colic			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	0 / 11 (0.00%)	5 / 506 (0.99%)	
occurrences causally related to treatment / all	0 / 0	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Thyroid mass			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Rhabdomyolysis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rheumatoid arthritis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Bronchopulmonary aspergillosis allergic			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective pulmonary exacerbation of cystic fibrosis			

subjects affected / exposed	0 / 11 (0.00%)	83 / 506 (16.40%)	
occurrences causally related to treatment / all	0 / 0	3 / 150	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial disease carrier			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19			
subjects affected / exposed	0 / 11 (0.00%)	4 / 506 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural infection			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest wall abscess			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic sinusitis			
subjects affected / exposed	0 / 11 (0.00%)	2 / 506 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			

subjects affected / exposed	0 / 11 (0.00%)	3 / 506 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective exacerbation of bronchiectasis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			
subjects affected / exposed	0 / 11 (0.00%)	7 / 506 (1.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parainfluenzae virus infection			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parotitis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 11 (0.00%)	6 / 506 (1.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia pseudomonal			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia viral			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			

subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound infection			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
subjects affected / exposed	0 / 11 (0.00%)	4 / 506 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinusitis			
subjects affected / exposed	0 / 11 (0.00%)	2 / 506 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular device infection			
subjects affected / exposed	0 / 11 (0.00%)	3 / 506 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal candidiasis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Diabetes mellitus inadequate control			

subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ketoacidosis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 506 (0.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	0 / 11 (0.00%)	2 / 506 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Extension Period: ELX/TEZ/IVA	Treatment Period: ELX/TEZ/IVA	
Total subjects affected by non-serious adverse events subjects affected / exposed	7 / 11 (63.64%)	501 / 506 (99.01%)	
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 11 (0.00%)	147 / 506 (29.05%)	
occurrences (all)	0	235	
Pain			
subjects affected / exposed	0 / 11 (0.00%)	37 / 506 (7.31%)	
occurrences (all)	0	43	
Influenza like illness			
subjects affected / exposed	0 / 11 (0.00%)	33 / 506 (6.52%)	
occurrences (all)	0	43	
Fatigue			
subjects affected / exposed	0 / 11 (0.00%)	118 / 506 (23.32%)	
occurrences (all)	0	205	
Malaise			
subjects affected / exposed	0 / 11 (0.00%)	26 / 506 (5.14%)	
occurrences (all)	0	42	
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	0 / 11 (0.00%)	45 / 506 (8.89%)	
occurrences (all)	0	56	
Immunisation reaction			
subjects affected / exposed	0 / 11 (0.00%)	83 / 506 (16.40%)	
occurrences (all)	0	164	
Respiratory, thoracic and mediastinal disorders			
Oropharyngeal pain			
subjects affected / exposed	1 / 11 (9.09%)	166 / 506 (32.81%)	
occurrences (all)	1	315	
Nasal congestion			
subjects affected / exposed	0 / 11 (0.00%)	113 / 506 (22.33%)	
occurrences (all)	0	184	
Lower respiratory tract congestion			
subjects affected / exposed	0 / 11 (0.00%)	37 / 506 (7.31%)	
occurrences (all)	0	52	

Haemoptysis			
subjects affected / exposed	1 / 11 (9.09%)	82 / 506 (16.21%)	
occurrences (all)	1	188	
Dyspnoea			
subjects affected / exposed	0 / 11 (0.00%)	62 / 506 (12.25%)	
occurrences (all)	0	104	
Cough			
subjects affected / exposed	0 / 11 (0.00%)	231 / 506 (45.65%)	
occurrences (all)	0	567	
Productive cough			
subjects affected / exposed	0 / 11 (0.00%)	61 / 506 (12.06%)	
occurrences (all)	0	91	
Respiration abnormal			
subjects affected / exposed	0 / 11 (0.00%)	33 / 506 (6.52%)	
occurrences (all)	0	47	
Wheezing			
subjects affected / exposed	0 / 11 (0.00%)	33 / 506 (6.52%)	
occurrences (all)	0	54	
Sputum increased			
subjects affected / exposed	0 / 11 (0.00%)	127 / 506 (25.10%)	
occurrences (all)	0	229	
Sinus congestion			
subjects affected / exposed	0 / 11 (0.00%)	62 / 506 (12.25%)	
occurrences (all)	0	102	
Rhinorrhoea			
subjects affected / exposed	0 / 11 (0.00%)	76 / 506 (15.02%)	
occurrences (all)	0	108	
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 11 (0.00%)	40 / 506 (7.91%)	
occurrences (all)	0	46	
Anxiety			
subjects affected / exposed	0 / 11 (0.00%)	38 / 506 (7.51%)	
occurrences (all)	0	48	
Insomnia			

subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	34 / 506 (6.72%) 39	
Investigations			
SARS-CoV-2 test positive subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	45 / 506 (8.89%) 50	
Weight decreased subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	32 / 506 (6.32%) 32	
Pulmonary function test decreased subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	30 / 506 (5.93%) 35	
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	26 / 506 (5.14%) 37	
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	72 / 506 (14.23%) 101	
Bacterial test positive subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	50 / 506 (9.88%) 82	
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	68 / 506 (13.44%) 82	
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	72 / 506 (14.23%) 91	
Blood bilirubin increased subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	31 / 506 (6.13%) 48	
Injury, poisoning and procedural complications			
Procedural pain subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	21 / 506 (4.15%) 23	

Cardiac disorders			
Palpitations			
subjects affected / exposed	1 / 11 (9.09%)	11 / 506 (2.17%)	
occurrences (all)	1	12	
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 11 (0.00%)	178 / 506 (35.18%)	
occurrences (all)	0	335	
Dizziness			
subjects affected / exposed	0 / 11 (0.00%)	38 / 506 (7.51%)	
occurrences (all)	0	49	
Gastrointestinal disorders			
Vomiting			
subjects affected / exposed	0 / 11 (0.00%)	67 / 506 (13.24%)	
occurrences (all)	0	96	
Nausea			
subjects affected / exposed	0 / 11 (0.00%)	91 / 506 (17.98%)	
occurrences (all)	0	141	
Diarrhoea			
subjects affected / exposed	0 / 11 (0.00%)	89 / 506 (17.59%)	
occurrences (all)	0	120	
Constipation			
subjects affected / exposed	0 / 11 (0.00%)	72 / 506 (14.23%)	
occurrences (all)	0	97	
Abdominal pain upper			
subjects affected / exposed	0 / 11 (0.00%)	49 / 506 (9.68%)	
occurrences (all)	0	72	
Abdominal pain			
subjects affected / exposed	0 / 11 (0.00%)	76 / 506 (15.02%)	
occurrences (all)	0	106	
Abdominal distension			
subjects affected / exposed	0 / 11 (0.00%)	31 / 506 (6.13%)	
occurrences (all)	0	42	
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	0 / 11 (0.00%)	57 / 506 (11.26%)	
occurrences (all)	0	78	

Acne subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	49 / 506 (9.68%) 57	
Musculoskeletal and connective tissue disorders			
Neck pain subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	9 / 506 (1.78%) 9	
Pain in extremity subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	34 / 506 (6.72%) 46	
Myalgia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	33 / 506 (6.52%) 38	
Back pain subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	51 / 506 (10.08%) 60	
Arthralgia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	71 / 506 (14.03%) 106	
Infections and infestations			
Gastroenteritis subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	31 / 506 (6.13%) 34	
Cystitis subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	8 / 506 (1.58%) 13	
COVID-19 subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	168 / 506 (33.20%) 208	
Vulvovaginal mycotic infection subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	27 / 506 (5.34%) 37	
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	36 / 506 (7.11%) 52	
Urinary tract infection			

subjects affected / exposed	0 / 11 (0.00%)	43 / 506 (8.50%)	
occurrences (all)	0	53	
Upper respiratory tract infection			
subjects affected / exposed	1 / 11 (9.09%)	120 / 506 (23.72%)	
occurrences (all)	1	223	
Sinusitis			
subjects affected / exposed	1 / 11 (9.09%)	76 / 506 (15.02%)	
occurrences (all)	1	126	
Rhinitis			
subjects affected / exposed	0 / 11 (0.00%)	50 / 506 (9.88%)	
occurrences (all)	0	110	
Pharyngitis			
subjects affected / exposed	0 / 11 (0.00%)	37 / 506 (7.31%)	
occurrences (all)	0	54	
Nasopharyngitis			
subjects affected / exposed	0 / 11 (0.00%)	154 / 506 (30.43%)	
occurrences (all)	0	335	
Lower respiratory tract infection			
subjects affected / exposed	1 / 11 (9.09%)	7 / 506 (1.38%)	
occurrences (all)	1	7	
Influenza			
subjects affected / exposed	0 / 11 (0.00%)	63 / 506 (12.45%)	
occurrences (all)	0	72	
Infective pulmonary exacerbation of cystic fibrosis			
subjects affected / exposed	3 / 11 (27.27%)	224 / 506 (44.27%)	
occurrences (all)	3	548	
Hordeolum			
subjects affected / exposed	1 / 11 (9.09%)	18 / 506 (3.56%)	
occurrences (all)	1	23	
Metabolism and nutrition disorders			
Hypoglycaemia			
subjects affected / exposed	0 / 11 (0.00%)	33 / 506 (6.52%)	
occurrences (all)	0	42	
Decreased appetite			

subjects affected / exposed	0 / 11 (0.00%)	26 / 506 (5.14%)	
occurrences (all)	0	29	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
13 April 2018	Updated the study drug regimen to include ivacaftor in place of VX-561 (deuterated ivacaftor), added the number of tablets subjects will receive and tablet strength, and updated guidance on missed doses to account for every 12 hours (q12h) dosing of ivacaftor; Updated statistical analysis plan section for clarity.
19 July 2018	Updated study drug interruption and stopping rules (removed exclusion criteria of isolated total bilirubin elevations).
09 August 2018	Added guidance on concomitant dosing of VX-445/TEZ/IVA with P-glycoprotein (gp) and CYP2C9 substrates based on medicines and healthcare products regulatory agency (MHRA) request.
08 November 2018	Clarified analysis plan for baseline definition and number of pulmonary exacerbations.
17 December 2019	Removed organic anion transporting polypeptides (OATP) 1B1 substrates from prohibited medications list; Added guidance on concomitant dosing of VX-445/TEZ/IVA with OATP1B1, OATP1B3, P-gp, and CYP2C9 substrates; Removed rate of change in percent predicted forced expiratory volume in 1 second (ppFEV1) from Additional Endpoints.
23 June 2020	Extended the Treatment Period to evaluate the long-term efficacy of VX-445/TEZ/IVA beyond 96 weeks of treatment.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported